Medscape Macrolide treatment of Mycoplasma pneumoniae may or may not benefit children with community-acquired lower respiratory tract infection (CA-LRTI), according to an article published in the June issue of Pediatrics. Eric Biondi, MD, from the Department of ...
CNNMoney The QLF, occupying 80 mu or over 13 acres, is approximately 18 miles from the Company's recently completed Jiangchuan macrolide (JCM) facility. The designed production capacity of QLF is 30% higher than the TPI's currently operating Longquan facility. and more »
PharmaTimes ... primary CABP pathogen being resistant to currently-approved macrolides, they are still one of the most commonly-used medicines for such infections, Cempr...
BioPharma Dive Cempra's antibiotic-in-development for treatment of community-acquired pneumonia (CAP), solithromycin, could become the first macrolide approved since 1988—and it could become a major part of the arsenal of drugs to combat antibiotic-resistant ...
ThePoultrySite.com UK - ECO Animal Health will be showcasing its innovative antimicrobial treatment, Aivlosin®, on its booth at IPPE. The Aivlosin products contain the novel macrolide , tylvalosin, which has been shown to have a number of benefits in poultry. In addition ...
The Pharma Letter Based on the nature of JCM's antibiotic business specializing on API manufacturing and sales, TPI's Jiangchuan macrolide facility (JCM), a wholly-owned subsidiary of Chengdu Tianyin, currently valued at $18 million, along with other assets under TPI ...
StreetInsider.com (subscription) Based on the nature of JCM's antibiotic business specializing on API manufacturing and sales, TPI's Jiangchuan macrolide facility (JCM), a wholly owned subsidiary of Chengdu Tianyin, currently valued at $18 million, along with other assets under TPI ... and more »
